CLSI & Viva Biotech Partnering Day: Zero-to-One

To successfully launch a biotech company, in addition to a brilliant idea and a great team, getting access to seed funding and drug R&D technology platforms are two important milestones. Whether you are an entrepreneur seeking early stage investment or you just have a project idea and would like to know how to take it to the next level, you are cordially invited to the Viva Biotech Partnering Reception. Drinks and Hors D’oeuvres will be served.

Why Viva

• Experienced – Biotech executives and scientific leaders-turned-investors
• Efficient – Streamlined due diligence and team decision-making process
• Focused – Invest only in biotech startups seeking early stage funding
• Rapid Growth – Invested in over 30 biotech startup companies over the last 3 years

How Viva can help you succeed

• Systematic and scientific incubation mechanism
• Easy access to talents and technology platforms

Agenda

About Viva Biotech

Viva Biotech Holdings, building upon its world-leading small molecule and biologics drug discovery CRO platforms, is dedicated to support early stage drug discovery. Viva adopts an innovative business model combining fee-for-service (FFS), equity-for-service (EFS) and direct investment approaches. Headquartered in Shanghai, with multiple incubators in China and an office in Cambridge, MA, USA., Viva could provide everything needed for a biotech startup including lab facilities, technicians, administrative support and drug R&D contract services. Since 2016, Viva has provided startup capitals in both seed and/or Series A rounds to help launch 30+ startup companies both in China and in the US. Viva is expecting to fund additional 30 companies in 2019. Learn more.